{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-003043","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.582301+00:00","generated_at":"2026-06-15T15:15:02.751346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aptose Q1 net loss widens to $13.7M; tuspetinib doublet dosing underway","bullets":["Net loss $13.7M ($0.15/sh) vs $11.5M ($0.12) YoY; R&D spend up to $8.8M.","Cash and investments $35.7M; runway through March 2024.","Tuspetinib APTIVATE trial: dose escalation/exploration complete; doublet with venetoclax dosing initiated with early blast reductions.","Safety review: no drug-induced myelosuppression or DLTs up to 160mg/day in >70 patients.","Anticipated FDA EOP1 meeting in Q2 2023 and clinical data presentation at EHA June 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-003043","json":"https://secwatch.observer/filing/0001171843-23-003043.json","markdown":"https://secwatch.observer/filing/0001171843-23-003043.md","text":"https://secwatch.observer/filing/0001171843-23-003043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184323003043/0001171843-23-003043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184323003043/f8k_050823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T15:15:02.751346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aed84eb0f21475f1a0f318bfcfcdca8ecd235664","claim":"Aptose Biosciences Inc. reported first quarter ended March 31, 2023 results: net income $ (13,676 ), EPS $ (0.15 ).","evidence_excerpt":"Aptose Biosciences, Inc. Statements of Operations Data (unaudited) ($ in thousands, except per share data) Three months ended March 31, 2023 March 31, 2022 Expenses: Research and development $ 8,811 $ 7,393 General and administrative 5,285 4,107 Operating expenses 14,096 11,500 Other income, net 420 19 Net loss $ (13,676 ) $ (11,481 ) Net Loss per share, Basic and diluted $ (0.15 ) $ (0.12 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184323003043/0001171843-23-003043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$ (13,676 )"},{"label":"EPS","value":"$ (0.15 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}